» Articles » PMID: 27183907

Combining 2-deoxy-D-glucose with Fenofibrate Leads to Tumor Cell Death Mediated by Simultaneous Induction of Energy and ER Stress

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 May 18
PMID 27183907
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Unregulated growth and replication as well as an abnormal microenvironment, leads to elevated levels of stress which is a common trait of cancer. By inducing both energy and endoplasmic reticulum (ER) stress, 2-Deoxy-glucose (2-DG) is particularly well-suited to take advantage of the therapeutic window that heightened stress in tumors provides. Under hypoxia, blocking glycolysis with 2-DG leads to significant lowering of ATP resulting in energy stress and cell death in numerous carcinoma cell types. In contrast, under normoxia, 2-DG at a low-concentration is not toxic in most carcinomas tested, but induces growth inhibition, which is primarily due to ER stress. Here we find a synergistic toxic effect in several tumor cell lines in vitro combining 2-DG with fenofibrate (FF), a drug that has been safely used for over 40 years to lower cholesterol in patients. This combination induces much greater energy stress than either agent alone, as measured by ATP reduction, increased p-AMPK and downregulation of mTOR. Inhibition of mTOR results in blockage of GRP78 a critical component of the unfolded protein response which we speculate leads to greater ER stress as observed by increased p-eIF2α. Moreover, to avoid an insulin response and adsorption by the liver, 2-DG is delivered by slow-release pump yielding significant anti-tumor control when combined with FF. Our results provide promise for developing this combination clinically and others that combine 2-DG with agents that act synergistically to selectively increase energy and ER stress to a level that is toxic to numerous tumor cell types.

Citing Articles

Altered metabolism in cancer: insights into energy pathways and therapeutic targets.

Tufail M, Jiang C, Li N Mol Cancer. 2024; 23(1):203.

PMID: 39294640 PMC: 11409553. DOI: 10.1186/s12943-024-02119-3.


The Combined Metabolically Oriented Effect of Fucoidan from the Brown Alga and Its Carboxymethylated Derivative with 2-Deoxy-D-Glucose on Human Melanoma Cells.

Malyarenko O, Usoltseva R, Silchenko A, Zueva A, Ermakova S Int J Mol Sci. 2023; 24(15).

PMID: 37569428 PMC: 10418387. DOI: 10.3390/ijms241512050.


2-Deoxy-D-Glucose: A Novel Pharmacological Agent for Killing Hypoxic Tumor Cells, Oxygen Dependence-Lowering in Covid-19, and Other Pharmacological Activities.

Singh R, Gupta V, Kumar A, Singh K Adv Pharmacol Pharm Sci. 2023; 2023:9993386.

PMID: 36911357 PMC: 9998157. DOI: 10.1155/2023/9993386.


Integrative transcriptome-wide analysis of atopic dermatitis for drug repositioning.

Song J, Kim D, Lee S, Jung J, Joo J, Jang W Commun Biol. 2022; 5(1):615.

PMID: 35729261 PMC: 9213508. DOI: 10.1038/s42003-022-03564-w.


The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.

Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T Pharmaceutics. 2022; 14(2).

PMID: 35213972 PMC: 8875291. DOI: 10.3390/pharmaceutics14020238.


References
1.
Li L, Fath M, Scarbrough P, Watson W, Spitz D . Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. Redox Biol. 2015; 4:127-35. PMC: 4309850. DOI: 10.1016/j.redox.2014.12.001. View

2.
Xi H, Kurtoglu M, Lampidis T . The wonders of 2-deoxy-D-glucose. IUBMB Life. 2014; 66(2):110-21. DOI: 10.1002/iub.1251. View

3.
Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M . Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther. 2004; 311(1):109-14. DOI: 10.1124/jpet.104.068312. View

4.
Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado O . 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res. 2011; 71(21):6796-806. DOI: 10.1158/0008-5472.CAN-11-0759. View

5.
Kurtoglu M, Philips K, Liu H, Boise L, Lampidis T . High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemother Pharmacol. 2009; 66(1):129-40. PMC: 2918425. DOI: 10.1007/s00280-009-1143-1. View